vs
PARKE BANCORP, INC.（PKBK）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是PARKE BANCORP, INC.的1.3倍（$30.3M vs $22.7M），PARKE BANCORP, INC.净利率更高（48.8% vs -221.3%，领先270.1%），REGENXBIO Inc.同比增速更快（43.0% vs 35.7%），PARKE BANCORP, INC.自由现金流更多（$39.0M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 22.6%）
Parke Bancorp, Inc.是总部位于美国的区域性银行控股公司，旗下运营Parke Bank，提供商业及零售银行全系列服务，包括存款产品、抵押贷款、小微企业融资、个人贷款等，主要服务新泽西州及费城大都会区域的客户。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
PKBK vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.3倍
$22.7M
营收增速更快
RGNX
高出7.3%
35.7%
净利率更高
PKBK
高出270.1%
-221.3%
自由现金流更多
PKBK
多$91.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
22.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $22.7M | $30.3M |
| 净利润 | $11.1M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 64.2% | -190.0% |
| 净利率 | 48.8% | -221.3% |
| 营收同比 | 35.7% | 43.0% |
| 净利润同比 | 49.8% | -31.2% |
| 每股收益（稀释后） | $0.93 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PKBKRGNX
| Q4 25 | $22.7M | $30.3M | ||
| Q3 25 | $21.0M | $29.7M | ||
| Q2 25 | $18.7M | $21.4M | ||
| Q1 25 | $17.4M | $89.0M | ||
| Q4 24 | $16.8M | $21.2M | ||
| Q3 24 | $15.6M | $24.2M | ||
| Q2 24 | $15.5M | $22.3M | ||
| Q1 24 | $15.1M | $15.6M |
净利润PKBKRGNX
| Q4 25 | $11.1M | $-67.1M | ||
| Q3 25 | $10.6M | $-61.9M | ||
| Q2 25 | $8.3M | $-70.9M | ||
| Q1 25 | $7.8M | $6.1M | ||
| Q4 24 | $7.4M | $-51.2M | ||
| Q3 24 | $7.5M | $-59.6M | ||
| Q2 24 | $6.5M | $-53.0M | ||
| Q1 24 | $6.2M | $-63.3M |
毛利率PKBKRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率PKBKRGNX
| Q4 25 | 64.2% | -190.0% | ||
| Q3 25 | 64.2% | -176.3% | ||
| Q2 25 | 59.0% | -296.3% | ||
| Q1 25 | 59.1% | 13.6% | ||
| Q4 24 | 58.0% | -242.1% | ||
| Q3 24 | 60.2% | -256.6% | ||
| Q2 24 | 56.7% | -251.3% | ||
| Q1 24 | 55.4% | -408.8% |
净利率PKBKRGNX
| Q4 25 | 48.8% | -221.3% | ||
| Q3 25 | 50.6% | -208.3% | ||
| Q2 25 | 44.3% | -331.8% | ||
| Q1 25 | 44.6% | 6.8% | ||
| Q4 24 | 44.2% | -241.3% | ||
| Q3 24 | 48.1% | -246.3% | ||
| Q2 24 | 41.6% | -237.7% | ||
| Q1 24 | 40.7% | -405.4% |
每股收益（稀释后）PKBKRGNX
| Q4 25 | $0.93 | $-1.30 | ||
| Q3 25 | $0.89 | $-1.20 | ||
| Q2 25 | $0.69 | $-1.38 | ||
| Q1 25 | $0.65 | $0.12 | ||
| Q4 24 | $0.61 | $-0.99 | ||
| Q3 24 | $0.62 | $-1.17 | ||
| Q2 24 | $0.53 | $-1.05 | ||
| Q1 24 | $0.51 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $324.5M | $102.7M |
| 总资产 | $2.2B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PKBKRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益PKBKRGNX
| Q4 25 | $324.5M | $102.7M | ||
| Q3 25 | $314.8M | $161.5M | ||
| Q2 25 | $312.2M | $213.7M | ||
| Q1 25 | $305.9M | $274.2M | ||
| Q4 24 | $300.1M | $259.7M | ||
| Q3 24 | $296.5M | $301.4M | ||
| Q2 24 | $292.8M | $348.3M | ||
| Q1 24 | $288.4M | $390.7M |
总资产PKBKRGNX
| Q4 25 | $2.2B | $453.0M | ||
| Q3 25 | $2.2B | $525.2M | ||
| Q2 25 | $2.2B | $581.0M | ||
| Q1 25 | $2.1B | $490.9M | ||
| Q4 24 | $2.1B | $466.0M | ||
| Q3 24 | $2.1B | $519.1M | ||
| Q2 24 | $2.0B | $569.4M | ||
| Q1 24 | $2.0B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $39.6M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $39.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | 171.3% | -174.0% |
| 资本支出强度资本支出/营收 | 2.6% | 1.7% |
| 现金转化率经营现金流/净利润 | 3.57× | — |
| 过去12个月自由现金流最近4个季度 | $63.5M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流PKBKRGNX
| Q4 25 | $39.6M | $-52.3M | ||
| Q3 25 | $11.4M | $-56.0M | ||
| Q2 25 | $6.8M | $-49.3M | ||
| Q1 25 | $7.0M | $33.6M | ||
| Q4 24 | $35.2M | $-31.6M | ||
| Q3 24 | $9.4M | $-40.5M | ||
| Q2 24 | $8.9M | $-45.5M | ||
| Q1 24 | $8.3M | $-55.5M |
自由现金流PKBKRGNX
| Q4 25 | $39.0M | $-52.8M | ||
| Q3 25 | $11.2M | $-56.5M | ||
| Q2 25 | $6.7M | $-49.7M | ||
| Q1 25 | $6.6M | $32.6M | ||
| Q4 24 | $35.0M | $-32.7M | ||
| Q3 24 | $9.4M | $-40.9M | ||
| Q2 24 | $8.9M | $-46.0M | ||
| Q1 24 | $8.3M | $-56.0M |
自由现金流率PKBKRGNX
| Q4 25 | 171.3% | -174.0% | ||
| Q3 25 | 53.5% | -189.9% | ||
| Q2 25 | 35.8% | -232.8% | ||
| Q1 25 | 38.0% | 36.6% | ||
| Q4 24 | 209.1% | -154.2% | ||
| Q3 24 | 60.0% | -168.9% | ||
| Q2 24 | 57.1% | -206.2% | ||
| Q1 24 | 55.1% | -358.5% |
资本支出强度PKBKRGNX
| Q4 25 | 2.6% | 1.7% | ||
| Q3 25 | 0.5% | 1.7% | ||
| Q2 25 | 0.3% | 1.8% | ||
| Q1 25 | 2.2% | 1.2% | ||
| Q4 24 | 0.7% | 5.1% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 0.2% | 2.1% | ||
| Q1 24 | 0.1% | 3.6% |
现金转化率PKBKRGNX
| Q4 25 | 3.57× | — | ||
| Q3 25 | 1.07× | — | ||
| Q2 25 | 0.82× | — | ||
| Q1 25 | 0.90× | 5.53× | ||
| Q4 24 | 4.75× | — | ||
| Q3 24 | 1.25× | — | ||
| Q2 24 | 1.38× | — | ||
| Q1 24 | 1.36× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PKBK
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
